The effect of polyamidoamine dendrimers on the in vitro cytotoxicity of paclitaxel in cultured prostate cancer (PC-3M) cells

Journal of Biomedical Nanotechnology

Volumn 3, Issue 4, 2007, Pages 384-393

  Devarakonda, Bharathi ^a,b   Judefeind, Anja ^a   Chigurupati, Srinivasulu ^b   Thomas, Shibu ^b   Shah, Girish V ^b   Otto, Daniel P ^a   de Villiers, Melgardt M ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF LOUISIANA AT MONROE   (United States)

Author keywords

Paclitaxel; PAMAM dendrimer; Prostate cancer

Indexed keywords

ANTINEOPLASTIC AGENT; DENDRIMER; PACLITAXEL; POLYAMIDOAMINE;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL NUCLEUS; CELL PROLIFERATION; CELL SHAPE; CELL SIZE; CELL STRUCTURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOSKELETON; DRUG APPROVAL; DRUG CYTOTOXICITY; DRUG RELEASE; DRUG SOLUBILITY; DRUG UPTAKE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; PROSTATE CANCER;

EID: 45849135648     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2007.047     Document Type: Article

References (46)

1. M. C. Wani, H. L. Taylor, M. E. Wall, P. C. Coogan, and A. J. McPail, Plant antitumor agents VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc. 93, 2325 (1971).
2. C. M. Spencer and D. Faulds, Paclitaxel. Drugs 48, 794 (1994).
3. S. B. Horwitz, Mechanism of action of taxol. Trends in Pharma. Sci. 13, 134 (1992).
4. R. Panchagnula, Pharmaceutical aspects of paclitaxel. Int. J. Pharm. 172, 1 (1998).
5. E. K. Rowinsky, On pushing the outer edge of the paclitaxel's dosing envelope. Clin. Cancer Res. 5, 481 (1999).
6. T. Osterberg and U. Norinder, Theoretical calculation and prediction of P-glycoprotein-interacting drugs using Mol Surf parametrization and PLS statistics. Eur. J. Pharm. 10, 295 (2000).
7. J. M. Gallo, S. Li, P. Guo, K. Reed, and J. Ma, The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice. Cancer Res. 63, 5114 (2003).
8. J. M. Koziara, P. R. Lockman, D. D. Allen, and R. J. Mumper, Paclitaxel nanoparticles for the potential treatment of brain tumors. J. Cont. Rel. 99, 259 (2004).
9. A. D'Emanuel, R. Jevprasesphant, J. Penny, and D. Attwood, The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability. J. Cont. Rel. 95, 447 (2004).
10. M. El-Sayed, C. A. Rhodes, M. Ginski, and H. Ghandehari, Transport mechanism(s) of poly(amidoamine) dendrimers across Caco-2 cell monolayers. Int. J. Pharm. 265, 151 (2003).
11. K. Singla, A. Garg, and D. Aggarwal, Paclitaxel and its formulations. Int. J. Pharm. 235, 179 (2002).
12. W. Lorenz, H. J. Reimann, A. Schmal, P. Dormann, B. Schwarz, E. Neugebauer, A. Doenicke, Histamine release in dogs by Cremophor El and its derivatives: Oxethylated oleic acid is the most effective constituent. Agents and Actions 7, 63 (1977).
13. R. B. Weiss, R. C. Donehower, P. H. Wiernik, T. Ohnuma, R. J. Gralla, D. L. Trump, J. R. Baker, D. A. VanEcho, D. D. VonHoff, and B. Leyland-Jones, Hypersensitivity reactions from taxol. J. Clin. Oncol. 8, 1263 (1990).
14. W. P. McGuire, E. K. Rowinsky, N. B. Rosenshein, F. C. Grumbine, D. S. Ettinger, D. K. Armstrong, and R. C. Donehower, Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasma. Ann. Intern. Med. 111, 273 (1989).
15. S. G. Arbuck, R. Canetta, N. Onetto, and M. C. Christian, Current dosage and schedule issues in the development of paclitaxol (Taxol®). Semin. Oncol. 20, 31 (1993).
16. C. D. Runowicz, P. H. Wiernik, A. I. Einzig, G. L. Goldberg, and S. B. Horwitz, Taxol in ovarian cancer. Cancer 71, 1591 (1993).
17. W. Waugh, L. Trissel, and V. Stella, Stability, comparability and plasticizer extraction of taxol (NSC-12593) injection diluted in infusion solutions and stored in various containers. Am. J. Hosp. Pharm. 48, 1520 (1991).
18. S. K. Dordunoo and H. M. Burt, Solubility and stability of taxol: Effects of buffers and cyclodextrins. Int. J. Pharm. 133, 191 ( 1996).
19. A. Niethammer, G. Gaedicke, H. N. Lode, and W. Wrasidlo, Synthesis and preclinical characterization of a paclitaxel prodrug with improved antitumor activity and water solubility. Bioconjugate Chem. 12, 414 (2001).
20. S. Lee, D. H. Seo, H. W. Kim, and S. Jung, Investigation of inclusion complexation of paclitaxel by cyclohenicosakis-(1→2)-(β-D-glucopyranosyl), by cyclic-(1→2)-β-D-glucans (cyclosophoraoses), and by cyclomaltoheptaoses (β-cyclodextrins). Carbohydr. Res. 334, 119 (2001).
21. M. M. Amiji, P. Lai, D. Shenoy, and M. Rao, Intratumoral administration of paclitaxel in an in situ gelling poloxamer 407 formulation. Pharm. Devel. Tech. 7, 195 (2002).
22. K. Kono, C. Kojima, T. Fukui, and T. Takagishi, Design of polyamidoamine dendrimers with poly(ethylene glycol) chains as drug carriers. Pol. Mat. Sci. and Eng. 84, 216 (2001).
23. S. C. Lee, G. Acharya, J. Lee, and K. Park, Hydrotropic polymers: Synthesis and characterization of polymers containing picolylnicotinamide moieties. Macromolecules 36, 2248 (2003).
24. Y. W. Cho, J. Lee, S. C. Lee, K. M. Huh, and K. Park, Hydrotropic agents for study of in vitro paclitaxel release from polymeric micelles. J. Cont. Rel. 97, 247 (2004).
25. T. Ooya, J. Lee, and K. Park, Effects of ethylene glycol-based graft, star-shaped, and dendritic polymers on solubilization and controlled release of paclitaxel. J. Cont. Rel. 93, 121 (2003).
26. T. Ooya, J. Lee, and K. Park, Hydrotropic dendrimers of generations 4 and 5: Synthesis, characterization, and hydrotropic solubilization of paclitaxel. Bioconjugate Chem. 15, 1221 (2004).
27. R. Esfand and D. A. Tomalia, Dendrimers and Other Dendritic Polymers, John Wiley, New York (2001), pp. 589-604.
28. B. Devarakonda, R. A. Hill, and M. M. De Villiers, The effect of PAMAM dendrimer generation size and surface functional group on the aqueous solubility of nifedipine. Int. J. Pharm. 284, 133 (2004).
29. B. Devarakonda, R. A. Hill, W. Liebenberg, M. Brits, and M. M. De Villiers, Comparison of the aqueous solubilization of practically insoluble paclitaxel by polyamidoamine (PAMAM) dendrimers and cyclodextrins. Int. J. Pharm. 304, 193 (2005).
30. B. Devarakonda, N. Li, and M. M. De Villiers, Effect of polyamidoamine (PAMAM) dendrimers on the in vitro release of water insoluble nifedipine from aqueous gels. AAPS PharmSciTech 6, Article 63, ( 2005), (http://www.aapspharmscitech.org).
31. B. Devarakonda and M. M. De Villiers, Development and validation of an HPLC method involving solid-phase extraction for the analysis of hydrophobic drugs in the presence of polyamidoamine (PAMAM) dendrimers, J. Liq. Chrom. Relat. Tech. 28, 2325 (2005).
32. T. Higuchi and K. A. Conners, Phase-Solubility Techniques, Advances in Analytical Chemistry and Instrumentation, edited by C. N. Reilly, John Wiley, New York (1965), pp. 117-212.
33. S. H. Yalkowsky, Solubility and Solubilization in Aqueous Media, Oxford University Press, New York, USA (1999).
34. 2. J. Phys. Chem. C 111, 4246 (2007).
35. M. C. Popescu, D. Filip, C. Vasile, C. Cruz, J. M. Rueff, M. Marcos, J. L. Serrano, and G. Singurel, Characterization by Fourier transform infrared spectroscopy (FT-IR) and 2D IR correlation spectroscopy of PAMAM dendrimer. J. Phys. Chem. B 110, 14198 (2006).
36. A. B. Dhanikula and R. Panchagnula, Preparation and characterization of water-soluble prodrug, liposomes and micelles of paclitaxel. Curr. Drug Deliv. 2, 75 (2005).
37. A. S. Chauhan, S. Sreedevi, K. B. Chalasani, A. K. Jain, S. K. Jian, N. K. Jain, and P. V. Diwan, Dendrimer-mediated transdermal delivery: Enhanced bioavailability of indomethacin. J. Cont. Rel. 90, 335 (2003).
38. D. A. Tomalia, A. M. Naylor, and W. A. Goddard III, Molecular-Level control of size, shape, surface chemistry, topology, and flexibility from atoms to macroscopic matter. Angew. Chem. Int. Ed. Engl. 29, 138 (1990).
39. J. Lee, S. C. Lee, G. Acharya, C. Chang, and K. Park, Hydrotropic solubilization of paclitaxel: Analysis of chemical structures for hydrotropic property. Pharm. Res. 20, 1022 (2003).
40. N. Baek, J. Lee, and K. Park, Aqueous N,N-diethylnicotinamide (DENA) solution as a medium for accelerated release study of paclitaxel. J. Biomater. Sci., Polym. Ed. 15, 527 (2004).
41. D. A. Tomalia, H. Baker, J. Dewald, M. Hall, G. Kallos, S. Martin, J. Roeck, J. Ryder, and P. A. Smith, A new class of polymers: Starbust-dendrimtic macromolecules. Polym. J. 17, 117 (1985).
42. M. F. Ottaviani, F Montalti, M. Romanelli, N. J. Turro, and D. A. Tomalia, Characterization of starburst dendrimers by EPR. 4. Mn(II) as a probe of interphase properties. J. Phys. Chem. 100, 11033 (1996).
43. W. Chen, D. A. Tomalia, and L. J. Thomas, Unusual pH-dependent polarity changes in PAMAM dendrimers: Evidence for pH-responsive conformational changes. Macromolecules 33, 9169 (2000).
44. B. S. McIntyre, K. P. Briski, M. A. Tirmenstein, M. W. Fariss, A. Gapor, and P. W. Sylvester, Antiproliferative and apoptotic effects of tocopherols and tocotrienols on normal mouse mammary epithelial cells. Lipids 35, 171 (2000).
45. S. W. Poxon, P. M. Mitchell, E. Liang, and J. A. Hughes, Dendrimer delivery of oligonucleotide. Drug Delivery 3, 255 (1996).
46. P. Kolhe, E. Misra, R. M. Kannan, S. Kanna, and M. Lieh-Lai, Drug complexation, in vitro release and cellular entry of dendrimers and hyperbranched polymers. Int. J. Pharm. 259, 143 (2003).